89 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Oncology & Haematology Audio PeerVoice

    • Science
    • 5.0 • 1 Rating

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents

    Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents

    Visit https://www.peervoice.com/HZH860 to view the entire programme with slides. After completing “Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents”, participants will be able to: Recall available safety and efficacy data evaluating the use of BTK inhibitors in the management of chronic lymphocytic leukaemia (CLL); and Implement evidence-based best practices for the management of CLL with BTK inhibitors, including sequencing alongside other agents (such as BCL-2 inhibitors) and switching between BTK inhibitors following adverse event (AE)-related discontinuation.

    • 21 min
    Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

    Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

    Visit https://www.peervoice.com/GYE860 to view the entire programme with slides. After completing “Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics”, participants will be able to: Assess available safety and efficacy data from randomised clinical trials evaluating first- and next-generation FLT3 inhibitors in acute myeloid leukaemia (AML); Implement best practice approaches to using FLT3 inhibitors in practice, including selecting between therapeutics and utilising recommended dose schedules; and Formulate adverse event management strategies for patients with newly diagnosed FLT3-mutant AML receiving a FLT3 inhibitor, including monitoring and supportive treatment.

    • 22 min
    Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

    Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

    Visit https://www.peervoice.com/UGT860 to view the entire programme with slides. After completing “Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer ”, participants will be able to: Assess the clinical relevance of randomised controlled trial (RCT) data evaluating the safety and efficacy of TROP2-directed therapies in the management of HR+/HER2- advanced breast cancer; and Identify patients with HR+/HER2- advanced breast cancer who may benefit from treatment with a TROP2-directed therapy.

    • 21 min
    Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

    Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

    Visit https://www.peervoice.com/NYE860 to view the entire programme with slides. After completing “Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy”, participants will be able to: Assess current treatment options for first-line management of advanced urothelial carcinoma (aUC), including maintenance therapy; Identify patients with aUC who may benefit from maintenance therapy; Formulate appropriate maintenance therapy plans for patients with aUC; and Identify emerging therapies, including maintenance therapies, for the management of aUC.

    • 16 min
    Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria

    Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria

    Visit https://www.peervoice.com/ZHK860 to view the entire programme with slides. After completing “Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria”, participants will be able to: Discuss the benefits and limitations of C5 inhibitors in the treatment of paroxysmal nocturnal haemoglobinuria (PNH); Differentiate between breakthrough haemolysis (BTH) and extravascular haemolysis (EVH) in patients who are receiving a terminal complement inhibitor; Evaluate clinically significant EVH in patients with PNH based on signs and symptoms; and Discuss key data on proximal complement inhibitors for the treatment of PNH and their role in clinical practice.

    • 19 min
    Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer

    Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer

    Visit https://www.peervoice.com/RAS860 to view the entire programme with slides. After completing “Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer”, participants will be able to: Identify non-invasive molecular testing approaches to identify biomarkers of interest in patients with metastatic colorectal cancer (mCRC); Formulate individualised first-line treatment plans for patients with mCRC, based on factors such as molecular status and primary tumour location; and Assess the clinical relevance of clinical trial data evaluating novel combination therapies for the management of mCRC.

    • 34 min

Customer Reviews

5.0 out of 5
1 Rating

1 Rating

Top Podcasts In Science

Hidden Brain
Hidden Brain, Shankar Vedantam
Technically Speaking: An Intel Podcast
iHeartPodcasts
Something You Should Know
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
Radiolab
WNYC Studios
Science Vs
Spotify Studios
Ologies with Alie Ward
Alie Ward

You Might Also Like

More by PeerVoice

PeerVoice Endocrinology & Metabolic Disorders Audio
PeerVoice
PeerVoice Heart & Lung Video
PeerVoice
PeerVoice Heart & Lung Audio
PeerVoice
PeerVoice Internal Medicine Video
PeerVoice
PeerVoice Immunology & Infectious Disease Video
PeerVoice
PeerVoice Internal Medicine Audio
PeerVoice